Inhibition of coagulation and inflammation by activated protein C or antithrombin reduces intestinal ischemia/reperfusion injury in rats

Critical Care Medicine

Volumn 32, Issue 6, 2004, Pages 1375-1383

  Schoots, Ivo G ^a   Levi, Marcel ^a   Van Vliet, Arlène K ^a   Maas, Adrie M ^a   Roossink, E H Paulina ^a   Van Gulik, Thomas M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Activated protein C; Antithrombin; Fibrin deposition; Fibrinolysis; Intestine; Ischemia and reperfusion injury

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTITHROMBIN; FIBRIN; HEPARIN; INTERLEUKIN 6; THROMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; CORRELATION ANALYSIS; FIBRIN DEPOSITION; FIBRINOLYSIS; HISTOPATHOLOGY; INFLAMMATION; INTESTINE FUNCTION; INTESTINE INJURY; INTESTINE ISCHEMIA; MALE; MESENTERIC ARTERY OCCLUSION; NONHUMAN; PORTAL VEIN BLOOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RAT; REPERFUSION; REPERFUSION INJURY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTITHROMBINS; BLOOD COAGULATION; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEPARIN; INJECTIONS, INTRAVENOUS; INTERLEUKIN-6; INTESTINES; MALE; PROSPECTIVE STUDIES; PROTEIN C; RANDOM ALLOCATION; RATS; RATS, WISTAR; REPERFUSION INJURY; THROMBIN;

EID: 2942627330     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000128567.57761.E9     Document Type: Article

References (51)

1. Pastores SM, Katz DP, Kvetan V: Splanchnic ischemia and gut mucosal injury in sepsis and the multiple organ dysfunction syndrome. Am J Gastroenterol 1996; 91:1697-1710
2. Arvidsson D, Rasmussen I, Almqvist P, et al: Splanchnic oxygen consumption in septic and hemorrhagic shock. Surgery 1991; 109:190-197
3. Dahn MS, Lange P, Lobdell K, et al: Splanchnic and total body oxygen consumption differences in septic and injured patients. Surgery 1987; 101:69-80
4. Massberg S, Enders G, Matos FC, et al: Fibrinogen deposition at the postischemic vessel wall promotes platelet adhesion during ischemia-reperfusion in vivo. Blood 1999; 94:3829-3838
5. Salter JW, Krieglstein CF, Issekutz AC, et al: Platelets modulate ischemia/reperfusion-induced leukocyte recruitment in the mesenteric circulation. Am J Physiol Gastrointest Liver Physiol 2001; 281:G1432-G1439
6. Schools IG, Levi M, Roossink EH, et al: Local intravascular coagulation and fibrin deposition on intestinal ischemia-reperfusion in rats. Surgery 2003; 133:411-419
7. Hashikura Y, Kawasaki S, Okumura N, et al: Prevention of hepatic artery thrombosis in pediatric liver transplantation. Transplantation 1995; 60:1109-1112
8. Yan SF, Mackman N, Kisiel W, et al: Hypoxia/hypoxemia-induced activation of the procoagulant pathways and the pathogenesis of ischemia-associated thrombosis. Arterioscler Thromb Vasc Biol 1999; 19:2029-2035
9. Gross PL, Aird WC: The endothelium and thrombosis. Semin Thromb Hemost 2000; 26:463-478
10. Opal SM, Kessler CM, Roemisch J, et al: Antithrombin, heparin, and heparin sulfate. Crit Care Med 2002; 30:8325-8331
11. Esmon CT: Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med 2001; 29:S48-S51
12. Opal SM: Therapeutic rationale for antithrombin III in sepsis. Crit Care Med 2000; 28:834-S37
13. Grinnell BW, Joyce D: Recombinant human activated protein C: A system modulator of vascular function for treatment of severe sepsis. Crit Care Med 2001; 29:853-860
14. Ostrovsky L, Woodman RC, Payne D, et al: Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation 1997; 96:2302-2310
15. Harada N, Okajima K, Kushimoto S, et al: Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood 1999; 93:157-164
16. Hoffmann JN, Vollmar B, Inthorn D, et al: Antithrombin reduces leukocyte adhesion during chronic endotoxemia by modulation of the cyclooxygenase pathway. Am J Physiol Cell Physiol 2000; 279:C98-C107
17. Ozden A, Sarioglu A, Demirkan NC, et al: Antithrombin III reduces renal ischemia-reperfusion injury in rats. Res Exp Med (Berl) 2001; 200:195-203
18. Comp PC, Esmon CT: Generation of fibrinolytic activity by infusion of activated protein C into dogs. J Clin Invest 1981; 68:1221-1228
19. Shibata M, Kumar SR, Amar A, et al: Antiinflammatory, antithrombotic, and neuro-protective effects of activated protein C in a murine model of focal ischemic stroke. Circulation 2001; 103:1799-1805
20. Mizutani A, Okajima K, Uchiba M, et al: Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood 2000; 95:3781-3787
21. Hirose K, Okajima K, Taoka Y, et al: Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation. Ann Surg 2000; 232:272-280
22. Yamaguchi Y, Hisama N, Okajima K, et al: Pretreatment with activated protein C or active human urinary thrombomodulin attenuates the production of cytokine-induced neutrophil chemoattractant following ischemia/reperfusion in rat liver. Hepatology 1997; 25:1136-1140
23. Stechmiller JK, Treloar D, Allen N: Gut dysfunction in critically ill patients: A review of the literature. Am J Crit Care 1997; 6:204-209
24. Gollin G, Zieg PM, Cohn SM, et al: Intestinal mucosal injury in critically ill surgical patients: Preliminary observations. Am Surg 1999; 65:19-21
25. Craane H, Emeis JJ, Lindeman J, et al: Immunoenzymehistochemical detection of fibrin microthrombi during disseminated intravascular coagulation rats. Histochemistry 1978; 57:97-105
26. Mizutani A, Okajima K, Uchiba M, et al: Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production. Blood 2003; 101:3029-3036
27. Hoffmann JN, Vollmar B, Romisch J, et al: Antithrombin effects on endotoxin-induced microcirculatory disorders are mediated mainly by its interaction with microvascular endothelium. Crit Care Med 2002; 30:218-225
28. Smorenburg SM, Vink R, te LM, et al: In vivo treatment of rats with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) does not affect experimentally induced colon carcinoma metastasis. Clin Exp Metastasis 1999; 17:451-456
29. Uchiba M, Okajima K, Murakami K: Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats. Thromb Res 1998; 89:233-241
30. Park PO, Haglund U, Bulkley GB, et al: The sequence of development of intestinal tissue injury after strangulation ischemia and reperfusion. Surgery 1990; 107:574-580
31. ten Cate H, Lamping RJ, Henny CP, et al: Automated amidolytic method for determining heparin, a heparinoid, and a low-Mr heparin fragment, based on their anti-Xa activity. Clin Chem 1984; 30:860-864
32. Elms MJ, Bunce IH, Bundesen PG, et al: Measurement of crosslinked fibrin degradation products - an immunoassay using monoclonal antibodies. Thromb Haemost 1983; 50:591-594
33. Verheijen JH, Mullaart E, Chang GT, et al: A simple, sensitive spectrophotometric assay for extrinsic (tissue- type) plasminogen activator applicable to measurements in plasma. Thromb Haemost 1982; 48:266-269
34. Levi M, de Boer JP, Roem D, et al: Plasminogen activation in vivo upon intravenous infusion of DDAVP. Quantitative assessment of plasmin-alpha 2-antiplasmin complex with a novel monoclonal antibody based radioimmunoassay. Thromb Haemost 1992; 67:111-116
35. Verburg M, Renes IB, Meijer HP, et al: Selective sparing of goblet cells and paneth cells in the intestine of methotrexate-treated rats. Am J Physiol Gastrointest Liver Physiol 2000; 279:G1037-G1047
36. Weitz JI, Hudoba M, Massel D, et al: Clotbound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86:385-391
37. Hoffmann JN, Vollmar B, Laschke MW, et al: Adverse effect of heparin on antithrombin action during endotoxemia: Microhemodynamic and cellular mechanisms. Thromb Haemost 2002; 88:242-252
38. Penner JA: Disseminated intravascular coagulation in patients with multiple organ failure of non-septic origin. Semin Thromb Hemost 1998; 24:45-52
39. Okada Y, Copeland BR, Fitridge R, et al: Fibrin contributes to microvascular obstructions and parenchymal changes during early focal cerebral ischemia and reperfusion. Stroke 1994; 25:1847-1853
40. Okajima K, Harada N, Kushimoto S, et al: Role of microthrombus formation in the development of ischemia/reperfusion-induced liver injury in rats. Thromb Haemost 2002; 88:473-480
41. Watkins JM, Spain DA, Krysztopik RJ, et al: Heparan preserves intestinal perfusion after hemorrhage and resuscitation. J Surg Res 1996; 66:154-158
42. Zabel DD, Hopf HW, Hunt TK: Transmural gut oxygen gradients in shocked rats resuscitated with heparan. Arch Surg 1995; 130:59-63
43. van der Poll T, Levi M, Hack CE, et al: Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994; 179:1253-1259
44. Stouthard JM, Levi M, Hack CE, et al: Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996; 76:738-742
45. Biemond BJ, Levi M, ten Cate H, et al: Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: Effect of interventions in the cytokine and coagulation cascades. Clin Sci (Colch) 1995; 88:587-594
46. Marder VJ, Feinstein DI, Francis CW, et al: Consumptive thrombohemorrhagic disorders. In: Hemostasis and thrombosis: basic principles and clinical practice. Third Edition (Colman RW, Hirsch J, Marder VJ, et al, Eds). Philadelphia, Lippincott, 1994, pp 1023-1063
47. Levi M, ten Cate H: Disseminated intravascular coagulation. N Engl J Med 1999; 341:586-592
48. Aoki N, Matsuda T, Saito H, et al: A comparative double-blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. Int J Hematol 2002; 75: 540-547
49. Warren BL, Eid A, Singer P, et al: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286:1869-1878
50. Acosta S, Nilsson TK, Bjorck M: Preliminary study of D-dimer as a possible marker of acute bowel ischaemia. Br J Surg 2001; 88:385-388
51. Turnage RH, Guice KS, Oldham KT: Pulmonary microvascular injury following intestinal reperfusion. New Horiz 1994; 2:463-475